MedTrace Logo

Serum NGAL IN Patients With Multiple Myeloma

NCT05439538 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-06-30

No results posted yet for this study

Summary

The aim of this study was to evaluate SERUM neutrophil gelatinase-associated lipocalin, emerging indicator of tubular damage and examine their relationship with established measures of renal function (serum creatinine, and estimated glomerular filtration rate, eGFR) among MM patients with and without renal impairment (RI), and at various stages of MM progression.

Conditions

  • Multiple Myeloma(MM)

Interventions

DIAGNOSTIC_TEST

SERUM NGAL

Study the sensitivity and the specificity of serum NGAL to detect AKI in myeloma

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Essam Abdel Monem El-beih,, professor · Assiut Univ

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-10-01
Completion
2025-01-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05439538 on ClinicalTrials.gov